Abstract:e21530 Background: Combination of anti-PD-1 plus anti-CTLA-4 has shown superior efficacy over monotherapy in advanced melanoma among Caucasian populations. However, it has not been evaluated in Chinese patients, and data on acral and mucosal melanoma are limited. We aimed to assess the efficacy and safety of anti-PD-1 antibody plus ipilimumab therapy in Chinese patients with advanced melanoma in clinical practice. Methods: Advanced melanoma patients treated with anti-PD-1 antibody combined with ipilimumab in Sun-Yat sen University Cancer Center from May 2015 to October 2022 were retrospectively assessed. Patient baseline characteristics, tumor responses (RECIST), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier analysis. Toxicity was assessed to estimate safety. Results: Altogether, 86 patients were included. The primary site was cutaneous, acral, mucosal, uveal and central nervous system (CNS) in 34, 21, 20, six and five patients, respectively. Among them, 21 patients were treatment-naive, 65 patients were previously treated, and 54 patients progressed of front-line ani-PD-1 therapy. 12 patients received ipilimumab 3mg/kg combined with low dose anti-PD-1 (Nivolumab 80mg or Pembrolizumab 1mg/kg) Q3w for four doses, and the other 74 patients received standard dose of anti-PD-1 plus ipilimumab 1mg/kg Q3w therapy. There were 25(29%) patients with liver metastasis and 26(30.2%) patients with CNS metastasis at baseline. The overall response rate (ORR) was 15.1% in the whole cohort, with complete response observed in six (6%) patients, partial response in 7 (8.1%), stable disease in 28 (32.6%). The response rate in the treatment-naive and prior systemic therapy group was 23.8% and 12.3%, respectively. For those treated with anti-PD-1 followed by the anti-PD-1+ ipilimumab as subsequent therapy after disease progression, the ORR was 11.1%. The response rate for cutaneous melanoma was 23.5%, and 37.5% in the naïve group. Response rates for acral, uveal, CNS and mucosal melanoma were 19.0%, 16.7%,0% and 0% respectively. The median progression-free survival (PFS) and overall survival (OS) in all patients was 4.5 (3.6-5.4) months and 22.0 (12.4-31.6) months, respectively. The 3-year OS were 100% in patients who achieved ORR. There were no significant differences in PFS or OS for patients with cutaneous or acral melanoma. mucosal primary tumor type, liver metastasis and elevated LDH were predictive of shorter PFS and OS. CNS metastasis, previous treatment, BRAF/NRAS mutation status and sex were not found to be related to survival. Adverse events occurred in 71% of patients and 13% were grade 3 or worse. Conclusions: The efficacy of anti-PD-1+ ipilimumab combination therapy in Chinese patients tended to be inferior compared to global studies but was well tolerated. OS were good in cases with CR or PR.

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy

Efficacy and Safety of Combined Anti-Angiogenic Chemoradiotherapy with PD-1 Monoclonal Antibody in Advanced Melanoma: A Retrospective Study.

Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma

The Efficacy of Anti-Pd-1 Combined with Temozolomide in Unresectable, Advanced Melanoma from One Center.

Salvage Therapy for Metastatic Acral or Mucosal Melanoma: Efficacy and Safety Analysis of Nab-Paclitaxel/carboplatin Combined with Bevacizumab in C-Kit/braf Wild-Type Pts.

Low-dose Nab-Paclitaxel-based Combination Chemotherapy in Heavily-Pretreated Pancreatic or Ampullary Cancer Patients: Taiwanese Single-Center Case Series.

Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China

Efficacy and safety of PD‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study

Efficacy of Salvage Therapies after Failure of Adjuvant Anti-Pd-1 Monotherapy for Melanoma in the Chinese Population: a Multi-Institutional Cohort Study

Real-world Efficacy and Safety of Axitinib in Combination with Anti-Programmed Cell Death-1 Antibody for Advanced Mucosal Melanoma

PD-1 Inhibitor Combined with Radiotherapy and GM-CSF As Salvage Therapy in Patients with Chemotherapy-Refractory Metastatic Solid Tumors.

Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.

Durable Response of the Triple Combination of Temozolomide, Sorafenib, and Bevacizumab As Second-Line Therapy for Patients with Stage Iv Acral Melanoma

Anti-PD-1 Plus Anti-Angiogenesis Combined with Chemotherapy in Patients with HER2-negative Advanced or Metastatic Gastric Cancer: a Multi-Institutional Retrospective Study.

Phase II Study of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Failure of Anti-Pd-1 Therapy.

Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Nab-Paclitaxel with or Without Bevacizumab As Second-Line Therapy or Beyond for Patients with Metastatic Non-Small-cell Lung Cancer.

Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects

Combination of Anti-Pd-1 Antibody with P-GEMOX As a Potentially Effective Immunochemotherapy for Advanced Natural Killer/t Cell Lymphoma